BTG (LON:BTG) said today that the 1st batch of patients in the European Union were treated with its DC Bead Lumi radiopaque drug-eluting bead. Two patients were treated for hepatocellular carcinoma and 1 patient was treated for malignant colorectal cancer metastasized to the liver.
The bead, which is the 1st commercially available radiopaque drug-eluting bead in the EU, uses doxorubicin or irinotecan to locally treat tumors.
Get the full story at our sister site, Drug Delivery Business News.